PTPN2 and neoplasm: PTPN2 has been proposed as a tumour suppressor, following several deletion and overexpression studies in haematological and solid malignancies (Kleppe et al. 2010; Karlsson et al. 2015; Shields et al. 2013; Hoshida et al. 2008; Lee et al. 2009).